Hôpital Haut-Lévêque, Avenue de Magellan, Bordeaux-Pessac, France.
Circulation. 2012 May 8;125(18):2184-96. doi: 10.1161/CIRCULATIONAHA.111.043216. Epub 2012 Apr 4.
Catheter ablation of ventricular tachycardia (VT) is effective and particularly useful in patients with frequent defibrillator interventions. Various substrate modification techniques have been described for unmappable or hemodynamically intolerable VT. Noninducibility is the most frequently used end point but is associated with significant limitations, so the optimal end point remains unclear. We hypothesized that elimination of local abnormal ventricular activities (LAVAs) during sinus rhythm or ventricular pacing would be a useful and effective end point for substrate-based VT ablation. As an adjunct to this strategy, we used a new high-density mapping catheter and frequently used epicardial mapping.
Seventy patients (age, 67±11 years; 7 female) with VT and structurally abnormal ventricle(s) were prospectively enrolled. Conventional mapping was performed in sinus rhythm in all, and a high-density Pentaray mapping catheter was used in the endocardium (n=35) and epicardially. LAVAs were recorded in 67 patients (95.7%; 95% confidence interval, 89.2-98.9). Catheter ablation was performed targeting LAVA with an irrigated-tip catheter placed endocardially via a transseptal or retrograde aortic approach or epicardially via the subxiphoid approach. LAVAs were successfully abolished or dissociated in 47 of 67 patients (70.1%; 95% confidence interval, 58.7-80.1). In multivariate analysis, LAVA elimination was independently associated with a reduction in recurrent VT or death (hazard ratio, 0.49; 95% confidence interval, 0.26-0.95; P=0.035) during long-term follow-up (median, 22 months).
LAVAs can be identified in most patients with scar-related VT. Elimination of LAVAs is feasible and safe and is associated with superior survival free from recurrent VT.
导管消融术治疗室性心动过速(VT)有效,尤其适用于频繁接受除颤器干预的患者。各种基质修饰技术已被用于描述不可标测或血液动力学不可耐受的 VT。无诱发性是最常使用的终点,但存在显著的局限性,因此最佳终点仍不清楚。我们假设窦性节律或心室起搏时消除局部异常心室活动(LAVA)将是基质为基础的 VT 消融的有用和有效终点。作为该策略的辅助手段,我们使用了新的高密度标测导管和经常使用的心外膜标测。
70 例 VT 合并结构异常心室的患者(年龄 67±11 岁;女性 7 例)前瞻性纳入本研究。所有患者均在窦性节律下进行常规标测,并在心内膜(n=35)和心外膜使用高密度 Pentaray 标测导管。67 例患者(95.7%;95%置信区间,89.2-98.9)记录到 LAVA。通过经房间隔或逆行主动脉途径心内膜内放置的灌流消融导管,或经剑突下入路心外膜内放置消融导管,靶向 LAVA 进行导管消融。在 67 例患者中,47 例(70.1%;95%置信区间,58.7-80.1)成功消除或分离 LAVA。多变量分析显示,LAVA 消除与减少复发性 VT 或死亡相关(风险比,0.49;95%置信区间,0.26-0.95;P=0.035),在长期随访(中位时间 22 个月)中。
大多数与瘢痕相关的 VT 患者都可以识别出 LAVA。消除 LAVA 是可行和安全的,与无复发性 VT 的生存率提高相关。